(Q40671369)

English

A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model

scientific article published on February 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model (English)

1 reference

Europe PubMed Central

22 September 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shima Uneda

1

1 reference

Europe PubMed Central

22 September 2017

Hiroyuki Hata

2

1 reference

Europe PubMed Central

22 September 2017

Fumihiko Matsuno

3

1 reference

Europe PubMed Central

22 September 2017

Akitoshi Nagasaki

4

1 reference

Europe PubMed Central

22 September 2017

Naoko Harada

5

1 reference

Europe PubMed Central

22 September 2017

Yumi Mitsuya

6

1 reference

Europe PubMed Central

22 September 2017

Hiromitsu Matsuzaki

7

1 reference

Europe PubMed Central

22 September 2017

Hiroaki Mitsuya

8

1 reference

Europe PubMed Central

22 September 2017

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

22 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

22 September 2017

120

1 reference

Europe PubMed Central

22 September 2017

3

1 reference

Europe PubMed Central

22 September 2017

396-404

1 reference

Europe PubMed Central

22 September 2017

Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

The L-arginine-nitric oxide pathway

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Vascular-specific growth factors and blood vessel formation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93)

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04078.X

21 January 2018

Identifiers

10.1046/J.1365-2141.2003.04078.X

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40671369&oldid=1904435691"